EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Breast cancer statistics for Japan in 2022: annual report of the national clinical database-breast cancer registry—clinical implications including chemosensitivity of breast cancer with low estrogen receptor expression

Masayuki Nagahashi, Hiraku Kumamaru, Naoko Kinukawa, Takayuki Iwamoto, Masahiro Kawashima, Takayuki Kinoshita, Takaaki Konishi, Yasuaki Sagara, Shinsuke Sasada, Shigehira Saji, Naoko Sanuki, Kenta Tanakura und 5 weitere

Breast Cancer · 2025-03 · 32 (2) · 217-226

DOI: 10.1007/s12282-025-01671-0 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Breast Cancer, online erschienen am 06.02.2025. Verfasst von Masayuki Nagahashi und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, Division of Breast and Endocrine Surgery, School of Medicine, Hyogo Medical University, 1-1 Mukogawa-Cho, Nishinomiya, Hyogo, …. Hauptthemen laut MEDLINE: Breast Neoplasms, Receptors, Estrogen. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Japanese Breast Cancer Society.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

This is an annual report by the Japanese Breast Cancer Society, which provides statistics on the clinical data on breast cancer in Japan, extracted from the National Clinical Database-Breast Cancer Registry (NCD-BCR). This report includes an update of 102,453 breast cancer cases at 1339 institutions registered in the NCD-BCR in 2022. Among the 101,793 female patients, the median age at cancer diagnosis was 62 years (interquartile range, 50–73 years), and 29.4% of the patients were premenopausal. Of these patients, 15,437 (15.2%) and 42,936 (42.2%) were diagnosed with stage 0 and I disease, respectively. Estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 (HER2) were positive in 78.7%, 69.4%, and 12.8% of the patients, respectively. Of the 97,154 patients without distant metastasis, 40,521 (41.7%) underwent breast-conserving surgery, and 5780 (5.9%) patients underwent some form of breast reconstruction procedures at the time of mastectomy. A total of 66,894 (68.9%) patients were treated with sentinel lymph node biopsy and 7155 (7.4%) patients were treated with sentinel lymph node biopsy followed by axillary node dissection. In the group of patients treated with breast-conserving surgery ( n = 40,521), 29,500 (72.8%) received whole-breast irradiation. In the group of patients who underwent mastectomy ( n = 54,476), 6226 (11.4%) received radiation therapy to the chest wall. Of the 13,950 patients receiving preoperative chemotherapy with or without molecular targeted therapy, 4308 (30.9%) achieved a pathological complete response, with the highest rate of 60.5% in patients with the hormone receptor-negative/HER2-positive subtype.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsReceptors, EstrogenHumansFemaleJapanMiddle AgedAgedRegistriesDatabases, FactualErb-b2 Receptor Tyrosine KinasesReceptors, ProgesteroneMastectomy, SegmentalMastectomy

Stichwörter der Autor:innen

Annual reportBreast neoplasmJapanese Breast Cancer SocietyNational clinical databaseRegistry

Substanzen

Receptors, EstrogenErb-b2 Receptor Tyrosine KinasesReceptors, ProgesteroneERBB2 protein, human

Autor:innen und Institutionen

  • Department of Surgery, Division of Breast and Endocrine Surgery, School of Medicine, Hyogo Medical University, 1-1 Mukogawa-Cho, Nishinomiya, Hyogo, 663-8501, Japan. ma-nagahashi@hyo-med.ac.jp.
  • Department of Healthcare Quality Assessment, The University of Tokyo Graduate School of Medicine, 7-3-1 Hongo, Bunkyo-Ku, Tokyo, 113-8655, Japan.
  • Breast and Thyroid Surgery, Kawasaki Medical School Hospital, 577 Matsushima, Kurashiki City, Okayama, 701-0192, Japan.
  • Department of Breast Surgery, Graduate School of Medicine, Kyoto University, 54 Shogoin-Kawahara-Cho, Sakyo-Ku, Kyoto, 606-8507, Japan.
  • Department of Breast Surgery, National Hospital Organization Tokyo Medical Center, 2-5-1, Higashigaoka, Meguro-Ku, Tokyo, 152-8902, Japan.
  • Department of Breast and Endocrine Surgery, Graduate School of Medicine, The University of Tokyo, 7-3-1 Hongo, Bunkyo-Ku, Tokyo, 113-8655, Japan.

Förderung

  • Japanese Breast Cancer Society

Zitieren

APA

Nagahashi, M., Kumamaru, H., Kinukawa, N., Iwamoto, T., Kawashima, M., Kinoshita, T., Konishi, T., Sagara, Y., Sasada, S., Saji, S., Sanuki, N., Tanakura, K., Niikura, N., Miyashita, M., Yoshida, M., Ishida, T., & Taira, N. (2025). Breast cancer statistics for Japan in 2022: annual report of the national clinical database-breast cancer registry—clinical implications including chemosensitivity of breast cancer with low estrogen receptor expression. Breast Cancer, 32(2), 217-226. https://doi.org/10.1007/s12282-025-01671-0

Vancouver

Nagahashi M, Kumamaru H, Kinukawa N, Iwamoto T, Kawashima M, Kinoshita T, et al. Breast cancer statistics for Japan in 2022: annual report of the national clinical database-breast cancer registry—clinical implications including chemosensitivity of breast cancer with low estrogen receptor expression. Breast Cancer. 2025;32(2):217-226. doi:10.1007/s12282-025-01671-0

BibTeX
@article{Nagahashi2025,
  author = {Nagahashi, Masayuki and Kumamaru, Hiraku and Kinukawa, Naoko and Iwamoto, Takayuki and Kawashima, Masahiro and Kinoshita, Takayuki and Konishi, Takaaki and Sagara, Yasuaki and Sasada, Shinsuke and Saji, Shigehira and Sanuki, Naoko and Tanakura, Kenta and Niikura, Naoki and Miyashita, Minoru and Yoshida, Masayuki and Ishida, Takanori and Taira, Naruto},
  title = {Breast cancer statistics for Japan in 2022: annual report of the national clinical database-breast cancer registry—clinical implications including chemosensitivity of breast cancer with low estrogen receptor expression},
  journal = {Breast Cancer},
  year = {2025},
  volume = {32},
  number = {2},
  pages = {217--226},
  doi = {10.1007/s12282-025-01671-0}
}
Kostenlos starten →